NCT07556731 Ferrous Succinate Anemia, Iron-Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07556731 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 22 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07556731 is a hot trial to watch
Anemia, Iron-Deficiency is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07556731 is notable because it evaluates Ferrous Succinate in a Phase 3 design sponsored by Hospital General de México. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07556731 |
| Official title | Comparison of Ferrous Salt vs. Liposomal Iron in Adult Women With Iron-Deficiency Anemia (IDA) |
| Phase / status | Phase 3 / Not yet recruiting |
| Intervention | Ferrous Succinate |
| Sponsor | Hospital General de México |
| Geography | Mexico |
| Enrollment | [object Object] |
| Primary endpoint | Change from baseline to 3 months in hemoglobin level (g/dL) |
| Endpoint time frame | Baseline and month 3 |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The goal of this study is to compare ferrous salt and liposomal iron for the treatment of iron-deficiency anemia in adult women. The study will also evaluate how well each treatment is tolerated. The main questions this study aims to answer are: Does liposomal iron increase hemoglobin levels as effectively as ferrous salt? Are there differences in side effects, especially gastrointestinal symptoms, between the treatments? Does dosing ferrous salt every other day improve tolerance compared to daily dosing? Researchers will compare three oral iron treatment strategies to determine which approach provides the best balance between effectiveness and tolerability. Participants will: Be adult women diagnosed with iron-deficiency anemia Be randomly assigned to one of three groups: Daily ferrous salt Ferrous salt taken every other day Daily liposomal iron Take the assigned iron treatment for 3 months Have blood tests at the beginning and end of
Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across Mexico shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Change from baseline to 3 months in hemoglobin level (g/dL) (Baseline and month 3) — Hemoglobin concentration will be measured at baseline and at 3 months after initiation of treatment. A favorable response will be defined as an increase of at least 2 g/dL from baseline.
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Ferrous Succinate is indexed as Small molecule drug, with target No normalized target returned, mechanism Iron preparation, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Hospital General de México did not return an exact normalized organization match in this snapshot. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07556731 provides a focused lens on Anemia, Iron-Deficiency development. Its value will be determined by whether Ferrous Succinate can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
